DEBATE - Biopharma Convergence - Is Asia Ready?
Biopharma convergence is the buzzword in the global pharmaceutical industry. Pipeline pressures and funding shortfalls are compelling the pharma and biotech firms to leverage each other's complementary core competencies. However, Asia is still in the process of catching up with this trend of biopharma convergence, and industry experts have their own opinions regarding its impact on the markets in Asia. To gain more insights on the trend, The Pharma Edge invited the following experts for a round table discussion:
John Wong
Regional Chair, Asia Pacific,
Boston Consulting Group
Kiran Mazumdar-Shaw CMD, Biocon Limited
Heather E Fraser
Global Life Sciences Lead,
IBM Institute for Business Value
F M Scherer
Professor,
Harvard University
Tom Newton
Pharmaceutical Market Analyst,
Visiongain
And this is what they had to say...
- On the driving forces behind the trend of biopharma convergence and what it means to the global pharma industry
- On the implications of this trend to pharma and biotech
- On the prevalence of this trend in the Asian pharmaceutical industry
- On the strategic issues involved in the biopharma convergence
- On the impact the emerging biopharmaceutical sector has on the chemical formulations segment
- On the hurdles to a successful biopharma convergence
- On the strategies the pharma companies should adopt to overcome these challenges
- On the impact of biopharma convergence on the Asian pharmaceutical industry in the future
